Be part of the knowledge.™

Global Oncology Academy

The Global Oncology Academy (GOA) is an educational platform for physicians and other healthcare professionals involved in oncology. Its mission is to increase knowledge regarding the disease course of specific cancers and address key elements for successful management. The GOA series will also share the science around innovations in combination therapies, oncology strategies, and new developments.

For more information about GOA, visit www.globaloncologyacademy.org.

873

LikeLikedUnlike

31-45 of 301

Beyond the Scalpel: When TGCT Surgery Isn’t the Solution
MinuteCE®
Beyond the Scalpel: When TGCT Surgery Isn’t the Solution
- Michiel van de Sande, MD, PhD
  Peer
1.00 program credits
Unlocking the CSF1R Code: Targeted Pathways and Tailored Choices
MinuteCE®
Unlocking the CSF1R Code: Targeted Pathways and Tailored Choices
- A.J. Gelderblom, MD, PhD
  Peer
1.00 program credits
Clinical Evidence in Focus: Interpreting Data on Systemic Therapy Targeting CSF1R
MinuteCE®
Clinical Evidence in Focus: Interpreting Data on Systemic Therapy Targeting CSF1R
- A.J. Gelderblom, MD, PhD
  Peer
1.00 program credits
Surgical Crossroads: Practical Considerations for Optimizing Treatment in TGCT
MinuteCE®
Surgical Crossroads: Practical Considerations for Optimizing Treatment in TGCT
- A.J. Gelderblom, MD, PhD
  Peer
- Michiel van de Sande, MD, PhD
  Peer
1.00 program credits
Emerging Evidence in Focus: Interpreting Data on Next-Generation CSF1R TKIs
MinuteCE®
Emerging Evidence in Focus: Interpreting Data on Next-Generation CSF1R TKIs
- A.J. Gelderblom, MD, PhD
  Peer
1.00 program credits
Applying the Evidence: TGCT Treatment Insights for Sports Medicine Physicians
MinuteCE®
Applying the Evidence: TGCT Treatment Insights for Sports Medicine Physicians
- A.J. Gelderblom, MD, PhD
  Peer
- Chelsea Cole, MD
  Peer
1.00 program credits
advertisement
The Safety Equation: Managing Adverse Events Associated With CSF1R Inhibitors in TGCT
MinuteCE®
The Safety Equation: Managing Adverse Events Associated With CSF1R Inhibitors in TGCT
- A.J. Gelderblom, MD, PhD
  Peer
1.00 program credits
Patient Perspective: Navigating TGCT Treatment—Surgery vs Systemic Therapy
MinuteCE®
Patient Perspective: Navigating TGCT Treatment—Surgery vs Systemic Therapy
- A.J. Gelderblom, MD, PhD
  Peer
1.00 program credits
All Sides of the Joint: Integrated TGCT Care Across Specialties
MinuteCE®
All Sides of the Joint: Integrated TGCT Care Across Specialties
- A.J. Gelderblom, MD, PhD
  Peer
- Michiel van de Sande, MD, PhD
  Peer
- Chelsea Cole, MD
  Peer
1.00 program credits
Giredestrant and Everolimus in HR+/HER2- Breast Cancer: Insights from evERA
Project Oncology®
Giredestrant and Everolimus in HR+/HER2- Breast Cancer: Insights from evERA
- Pavani Chalasani, MD, MPH
  Peer
- Erica L. Mayer, MD, MPH
  Peer
SERENA-6: Assessing Camizestrant’s Impact in HR+/HER2- Breast Cancer
Project Oncology®
SERENA-6: Assessing Camizestrant’s Impact in HR+/HER2- Breast Cancer
- Pavani Chalasani, MD, MPH
  Peer
- Erica L. Mayer, MD, MPH
  Peer
Dato-DXd’s Intracranial Efficacy in NSCLC: Insights from TROPION-Lung01
Project Oncology®
Dato-DXd’s Intracranial Efficacy in NSCLC: Insights from TROPION-Lung01
- Jacob Sands, MD
  Peer
- Aaron Lisberg, MD
  Peer
advertisement
Dato-DXd in Non-Small Cell Lung Cancer: Implications of TROPION-Lung01 Data
Project Oncology®
Dato-DXd in Non-Small Cell Lung Cancer: Implications of TROPION-Lung01 Data
- Jacob Sands, MD
  Peer
- Julia Rotow, MD
  Peer
- Xiuning Le, MD, PhD
  Peer
Growth Recovery After Tovorafenib in Pediatric Low-Grade Gliomas: New Data
Project Oncology®
Growth Recovery After Tovorafenib in Pediatric Low-Grade Gliomas: New Data
- Alexandria May, PharmD, BCPS
  Peer
- Daniel Landi, MD
  Peer
Advancing Endometrial Cancer Care: Molecular Targets and Emerging Therapies
Project Oncology®
Advancing Endometrial Cancer Care: Molecular Targets and Emerging Therapies
- Casey Cosgrove, MD
  Peer

Program Chapters

Segment Chapters

Playlist:

Recommended